旁系CMV阳性与阴性供者对异基因造血干细胞移植结局的影响
该回顾性队列研究分析了126例CMV血清学阳性、接受单倍体移植的患者,比较CMV阴性供者与旁系CMV阳性供者的CMV相关事件及生存结局。结果显示CMV阴性供者增加难治性CMV血症风险,来特莫韦可降低但未消除该差异,两组总体生存相当。
要点
- CMV阴性供者组难治性CMV血症发生率显著高于旁系CMV阳性供者组。
- 来特莫韦预防可延迟首次CMV血症发生并降低难治性CMV血症发生率。
- 两种供者来源的3年总生存、非复发死亡及累积复发率无显著差异。
核心结论
- CMV阴性供者增加受者CMV相关事件风险,来特莫韦可改善但难治性CMV血症发生率仍高于旁系CMV阳性供者组,总体生存结局相当。
研究设计与样本
- 回顾性队列研究,纳入2017年1月至2025年3月北京大学人民医院126例CMV血清学阳性、接受单倍体移植的患者。
- 来特莫韦上市前:CMV阴性供者组16例,旁系CMV阳性供者组58例;上市后:CMV阴性供者组27例,旁系CMV阳性供者组25例。
主要发现
- 来特莫韦上市前,CMV阴性供者组难治性CMV血症发生率87.5%对50.0%(P=0.007),首次CMV血症持续中位时间29天对17天(P=0.004)。
- 来特莫韦将首次CMV血症发生时间从37天延迟至140天(CMV阴性供者组,P<0.001),从36天延迟至111天(旁系CMV阳性供者组,P=0.013)。
- 应用来特莫韦时,两组首次CMV血症持续中位时间差异无统计学意义(18天对12天,P=0.313)。
- 来特莫韦降低CMV阴性供者组难治性CMV血症发生率(40.7%对87.5%,P=0.003),但仍高于旁系CMV阳性供者组(40.7%对12.0%,P=0.020)。
- 无论是否应用来特莫韦,两组3年总生存率、非复发相关死亡率、累积复发率差异均无统计学意义(P值均>0.05)。
关键数值与推荐
- CMV疾病是总生存(HR=3.0,95%CI:1.3~7.3,P=0.014)和非复发相关死亡(HR=3.1,95%CI:1.1~8.8,P=0.035)的独立危险因素。
- 难治性CMV血症是CMV疾病的独立危险因素(HR=12.0,95%CI:2.9~50.7,P=0.001)。
- 无来特莫韦预防的CMV阴性供者是难治性CMV血症的独立危险因素(P=0.005)。
临床怎么用
- 对CMV血清学阳性受者,优先选择旁系CMV阳性供者可能降低难治性CMV血症风险。
- 使用来特莫韦预防可延迟CMV血症发生并降低难治性CMV血症发生率,但CMV阴性供者组风险仍较高。
- 需重视难治性CMV血症的监测与干预,以降低CMV疾病及相关死亡风险。
局限性
- 回顾性单中心研究,样本量有限,来特莫韦上市前后分组样本不均衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the impact of collateral cytomegalovirus (CMV) -positive versus CMV-negative donors on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Method: This retrospective cohort study analyzed CMV-related events and survival outcomes in allo-HSCT recipients with CMV seropositive who received grafts from CMV-negative (CMV-negative donor group) or collateral CMV-positive (collateral CMV-positive donor group) haploidentical donors at Peking University People's Hospital from January 2017 to March 2025. Results: A total of 126 patients were enrolled, including 16 CMV-negative and 58 collateral CMV-positive donors before the availability of letermovir, and 27 CMV-negative and 25 collateral CMV-positive donors after the availability of letermovir. With a median follow-up of 1 091 (660, 1 536) days, before the availability of letermovir in China, the CMV-negative donor group had a significantly higher incidence of refractory CMV viremia (87.5% vs 50.0%, P=0.007) and a longer median duration of first CMV viremia [29 (95% CI: 25-33) vs 17 (95% CI: 15-19) days, P=0.004] than the collateral CMV-positive donor group. The use of letermovir significantly delayed the onset of first post-transplant CMV viremia in both groups: from day 37 (95% CI: 31-43) to day 140 (95%CI: 136-144) in the CMV-negative donor group (P<0.001) and from day 36 (95% CI: 33-39) to day 111 (95% CI: 76-146) in the collateral CMV-positive donor group (P=0.013). With letermovir prophylaxis, the difference in the median duration of the first CMV viremia between the CMV-negative and collateral CMV-positive donor groups was no longer significant [18 (95% CI: 17-19) vs 12 (95%CI: 0-25) days, P=0.313]. Letermovir reduced the incidence of refractory CMV viremia in the CMV-negative donor group (40.7% vs 87.5%, P=0.003), but the incidence remained higher than that in the collateral CMV-positive donor group (40.7% vs 12.0%, P=0.020). Regardless of letermovir use, there were no statistically significant differences in the 3-year overall survival, non-relapse mortality, or cumulative relapse rate between the CMV-negative and collateral CMV-positive donor groups (all P>0.05). Multivariate analysis showed that CMV disease was an independent risk factor for overall survival (HR=3.0, 95%CI: 1.3-7.3, P=0.014) and non-relapse mortality (HR=3.1, 95%CI: 1.1-8.8, P=0.035). Refractory CMV viremia was an independent risk factor for CMV disease (HR=12.0, 95%CI: 2.9-50.7, P=0.001). Logistic regression analysis showed that having a CMV-negative donor status without letermovir prophylaxis was an independent risk factor for refractory CMV viremia (P=0.005) . Conclusion: CMV-negative donors increase the risk of CMV-related events in recipients. Although letermovir prophylaxis mitigates this risk, the incidence of refractory CMV viremia remains higher in the CMV-negative donor group than in the collateral CMV-positive donor group, whereas the overall survival outcomes are comparable between the two donor sources. 目的: 探索旁系巨细胞病毒(CMV)阳性和CMV阴性供者对异基因造血干细胞移植(allo-HSCT)结局的影响。 方法: 本项回顾性队列研究分析了2017年1月至2025年3月在北京大学人民医院接受CMV阴性单倍体供者(CMV阴性供者组)和旁系CMV阳性单倍体供者(旁系CMV阳性供者组)来源移植物的allo-HSCT患者的CMV相关事件和生存结局,患者的CMV血清学均为阳性。 结果: 本研究共纳入126例患者,来特莫韦在国内上市前,CMV阴性供者组16例,旁系CMV阳性供者组58例;来特莫韦在国内上市后,CMV阴性供者组27例,旁系CMV阳性供者组25例。中位随访1 091(660,1 536)d,来特莫韦在国内上市前,CMV阴性供者组难治性CMV血症发生率(87.5%对50.0%,P=0.007)和首次CMV血症持续中位时间[29(95%CI:25~33)d对17(95%CI:15~19)d,P=0.004]明显高于旁系CMV阳性供者组。来特莫韦的应用显著推迟了两组患者移植后首次CMV血症的发生时间:CMV阴性供者组从移植后37(95%CI:31~43)d延迟至140(95%CI:136~144)d(P<0.001);旁系CMV阳性供者组从移植后36(95%CI:33~39)d延迟至移植后111(95%CI:76~146)d(P=0.013)。应用来特莫韦的情况下,CMV阴性供者组和旁系CMV阳性供者组首次CMV血症持续中位时间的差异无统计学意义[18(95%CI:17~19)d和12(95%CI:0~25)d,P=0.313]。来特莫韦的应用降低了CMV阴性供者组难治性CMV血症的发生率(40.7%对87.5%,P=0.003),但仍高于旁系CMV阳性供者组(40.7%对12.0%,P=0.020)。无论是否应用来特莫韦,CMV阴性供者组和旁系CMV阳性供者组3年总生存率、非复发相关死亡率、累积复发率的差异均无统计学意义(P值均>0.05)。多因素分析显示,CMV疾病是影响患者总生存(HR=3.0,95%CI:1.3~7.3,P=0.014)和非复发相关死亡(HR=3.1,95%CI:1.1~8.8,P=0.035)的独立危险因素。CMV疾病发生的独立危险因素为难治性CMV血症(HR=12.0,95%CI:2.9~50.7,P=0.001)。Logistic回归分析显示,难治性CMV血症发生的独立危险因素为无来特莫韦预防的CMV阴性供者(P=0.005)。 结论: CMV阴性供者会增加受者CMV相关事件的发生风险。来特莫韦的应用虽可改善这一情况,但CMV阴性供者组难治性CMV血症的发生率仍高于旁系CMV阳性供者组,两种供者来源的受者总体生存结局相当。.
引用
- Liu J, Zhang YY, Mo XD, et al. [The impact of collateral CMV-seropositive and CMV-seronegative donors on the outcomes of allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42851177. doi:10.3760/cma.j.cn121090-20251016-00470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。